Short Communication

Hypertensive toxicity of thyrosine kinase inhibitors; Friend or Foe?

Yusuf Ziya Şener* and Ergün Barış Kaya

Published: 12 January, 2021 | Volume 5 - Issue 1 | Pages: 001-002

Tyrosine kinase inhibitors (TKIs) are widely used in Oncology practice. Hypertension may develop during cancer treatment and TKIs are well known drugs that are associated with drug related hypertensive toxicity. TKI related hypertensive toxicity is not always the indicator of worse clinical outcomes and it may be the sign of treatment efficacy.

Read Full Article HTML DOI: 10.29328/journal.ach.1001025 Cite this Article Read Full Article PDF


  1. Dobbin SJH, Petrie MC, Myles RC, Touyz RM, Lang NN. Cardiotoxic effects of angiogenesis inhibitors. Clin Sci (Lond). 2021; 135: 71-100. PubMed: https://pubmed.ncbi.nlm.nih.gov/33404052/
  2. Pottier C, Fresnais M, Gilon M, Jérusalem G, Longuespée R, et al. Tyrosine kinase inhibitors in cancer: breakthrough and challenges of targeted therapy. Cancers (Basel). 2020; 12: 731. PubMed: https://pubmed.ncbi.nlm.nih.gov/32244867/
  3. Ptinopoulou AG, Sprangers B. Tyrosine kinase inhibitor-induced hypertension—marker of anti-tumour treatment efficacy or cardiovascular risk factor? Clin Kidney J. sfaa174.
  4. Chung R, Tyebally S, Chen D, Kapil V, Walker JM, et al. Hypertensive Cardiotoxicity in Cancer Treatment-Systematic Analysis of Adjunct, Conventional Chemotherapy, and Novel Therapies-Epidemiology, Incidence, and Pathophysiology. J Clin Med. 2020; 9: 3346. PubMed: https://pubmed.ncbi.nlm.nih.gov/33081013/
  5. Maitland ML, Bakris GL, Black HR, Chen HX, Durand JB, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst. 2010; 102: 596–604. PubMed: https://pubmed.ncbi.nlm.nih.gov/20351338/
  6. Kandula P, Agarwal R. Proteinuria and hypertension with tyrosine kinase inhibitors. Kidney Int. 2011; 80: 1271–1277. PubMed: https://pubmed.ncbi.nlm.nih.gov/21900879/
  7. Wirth LJ, Tahara M, Robinson B, Francis S, Brose MS, et al. Treatment-emergent hypertension and efficacy in the phase 3 study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT). Cancer. 2018; 124: 2365–2372. PubMed: https://pubmed.ncbi.nlm.nih.gov/29656442/
  8. Pandey AK, Singhi EK, Arroyo JP, Ikizler TA, Gould ER, et al. Mechanisms of VEGF inhibitor-associated hypertension and vascular disease. Hypertension 2018; 71: e1–e8. PubMed: https://pubmed.ncbi.nlm.nih.gov/29279311/
  9. Yang X, Pan X, Cheng X, Kuang Y, Cheng Y. Risk of Hypertension with Sorafenib Use in Patients with Cancer: A Meta-Analysis From 20,494 Patients. Am J Ther. 2017; 24: e81–e101. PubMed: https://pubmed.ncbi.nlm.nih.gov/26322676/
  10. Rini BI, Schiller JH, Fruehauf JP, Cohen EE, Tarazi JC, et al. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res. 2011; 17: 3841–3849. PubMed: https://pubmed.ncbi.nlm.nih.gov/21531811/

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More